PCMP-E51 Antibody

What is PCMP-E51 antibody and how is it classified?

PCMP-E51 is a CD4-induced (CD4i) antibody that recognizes epitopes on the HIV-1 envelope glycoprotein (Env) that become exposed after CD4 binding. E51 belongs to a specialized class of CD4i antibodies that incorporate sulfotyrosines into their heavy-chain CDR3 regions, which enables them to mimic the CCR5 co-receptor interaction with gp120 . This structural mimicry allows E51 to bind highly conserved pockets on gp120 that normally recognize the CCR5 amino terminus, making it a valuable tool in HIV-1 neutralization research .

How does the structure of E51 differ from other CD4i antibodies?

E51 contains sulfotyrosines in its heavy-chain CDR3 region that structurally mimic the CCR5 co-receptor, distinguishing it from other CD4i antibodies like 17b that lack this feature . These sulfotyrosines bind to highly conserved pockets on gp120, specifically located at the base of the third variable loop and in the fourth conserved domain . This structural specialization enables E51 to typically bind Env and neutralize HIV-1 more efficiently than non-sulfotyrosine containing CD4i antibodies .

What is the typical functional assay approach for evaluating E51 antibody activity?

E51 antibody activity is typically evaluated through neutralization assays against multiple HIV-1 isolates. The standard approach involves:

• Incubating serial dilutions of E51 antibody with pseudoviruses or live HIV-1 isolates

• Adding the mixture to target cells (typically TZM-bl cells)

• Measuring infection levels after 48-72 hours

• Calculating the IC50 values (concentration required for 50% inhibition)

The resulting dose-response curves can be modeled using a four-parameter logistic equation:

$y = L+(U - L)/(1 + (x/IC50)^h)$

Where L is the minimum value, U is the maximum value, IC50 is the inflection point, and h is the Hill slope determining curve steepness .

How does E51 bind to the HIV-1 envelope glycoprotein?

E51 binds to the co-receptor binding site on HIV-1 gp120 that becomes exposed after CD4 binding. The binding mechanism involves:

• Initial CD4 binding to gp120 induces conformational changes

• These changes expose the co-receptor binding site

• E51's sulfotyrosine-containing CDR-H3 region engages with the sulfotyrosine-binding pockets on gp120

• These pockets are located at the base of the third variable loop (V3) and in the fourth conserved domain (C4) of gp120

This binding mimics the natural interaction between gp120 and CCR5 co-receptor, effectively blocking viral entry by competing with CCR5 for binding to the exposed site .

What role do sulfotyrosines play in E51's function and how can they be analyzed?

Sulfotyrosines in E51's heavy-chain CDR3 region are critical for its function as they:

• Mimic the sulfotyrosines present in the CCR5 N-terminus

• Bind to conserved pockets on gp120 that recognize the CCR5 amino terminus

• Provide higher binding affinity and neutralization capacity compared to CD4i antibodies without sulfotyrosines

For analyzing sulfotyrosines:

• Mass spectrometry can confirm the presence and position of sulfotyrosines

• Alanine scanning mutagenesis can identify which sulfotyrosines are critical for binding

• Comparison of binding kinetics between wild-type and desulfated variants can quantify the contribution of sulfation

• Crystallographic studies can reveal the precise molecular interactions between sulfotyrosines and gp120 binding pockets

How does E51 interact synergistically with CD4-binding site antibodies like VRC01?

Research has demonstrated that E51 exhibits remarkable synergy with CD4-binding site (CD4bs) antibodies like VRC01 through a mechanism involving conformational modulation of the HIV-1 Env trimer:

• E51 induces favorable quaternary conformations in the Env trimer that increase binding affinity for CD4bs antibodies

• At fixed total concentrations, mixtures of E51 and VRC01 neutralize HIV-1 isolates more efficiently than either antibody alone

• E51 promotes association of CD4bs antibodies to the Env trimer but not to monomeric gp120

• This effect is specific to certain CD4bs antibodies; for example, E51 enhanced binding of VRC01, NIH45-46, and 3BNC117, but had minimal effect on CD4-Ig or b12

This synergistic effect is quantified in the table below, showing IC50 values (μg/ml) for individual antibodies versus combinations:

Data derived from neutralization experiments described in .

What experimental approaches can be used to investigate E51's synergy with other antibodies?

To investigate E51's synergistic effects with other antibodies, researchers can employ several methodological approaches:

• Neutralization assays with antibody combinations:

  • Test different ratios of E51 with CD4bs antibodies

  • Calculate combination indices (CI) using the Chou-Talalay method

  • Generate isobolograms to visualize synergy

• Binding assays to cell-expressed Env trimers:

  • Express HIV-1 Env trimers on cell surfaces

  • Pre-incubate cells with one antibody (e.g., E51)

  • Measure binding of the second antibody (e.g., VRC01) using flow cytometry

  • Compare binding with and without the first antibody

• Structural studies:

  • Use cryo-electron microscopy to visualize Env conformational changes

  • Perform hydrogen/deuterium exchange mass spectrometry to detect allosteric effects

  • Employ FRET-based assays to monitor real-time conformational changes

• Surface plasmon resonance (SPR) analyses:

  • Immobilize one antibody on the sensor chip

  • Flow Env protein over the surface

  • Inject the second antibody and measure binding enhancement or inhibition

How can E51 be engineered to improve its therapeutic potential?

Engineering approaches to enhance E51's therapeutic potential include:

• Affinity maturation:

  • Directed evolution using phage or yeast display

  • Computational design of CDR regions for improved binding

  • Focus on optimizing the sulfotyrosine interactions with gp120

• Bi-specific antibody development:

  • Creation of dual-targeting antibodies combining E51 with CD4bs binders

  • Engineering E51-based molecules that target both Env and cell receptors

  • Fusion of E51 single-chain variable fragments (scFv) with other antibody domains

• Fc engineering:

  • Modification of Fc regions to enhance effector functions

  • Increasing half-life through Fc mutations that enhance FcRn binding

  • Engineering to improve tissue penetration

• CCR5-mimetic optimization:

  • Development of CCR5mim2-Ig based on E51's CDR-H3 region

  • Further optimization of sulfotyrosine positioning and additional binding determinants

  • Incorporation of E51-derived peptides into fusion inhibitors

What methodologies are most effective for analyzing E51 binding to different HIV-1 Env variants?

For comprehensive analysis of E51 binding to HIV-1 Env variants, several complementary methodologies are recommended:

• ELISA-based binding assays:

  • Immobilize gp120 monomers or trimers from different HIV-1 clades

  • Apply E51 at various concentrations

  • Use murine IgG2a Fc-exchanged E51 to distinguish from other antibodies in competition assays

  • Calculate EC50 values to compare binding affinities

• Cell-based binding assays:

  • Express Env trimers on cell surfaces

  • Measure E51 binding using flow cytometry

  • Compare binding to different Env variants and mutants

  • Analyze the effect of CD4 presence on binding efficiency

• Surface plasmon resonance:

  • Determine binding kinetics (kon, koff) and affinity (KD)

  • Analyze thermodynamic parameters of the interaction

  • Study the effect of pH and ionic strength on binding

• Epitope mapping approaches:

  • Alanine scanning mutagenesis of gp120

  • Hydrogen/deuterium exchange mass spectrometry

  • X-ray crystallography or cryo-EM of E51-gp120 complexes

  • Computational docking and molecular dynamics simulations

What are the main technical challenges in producing and purifying functional E51 antibody?

Producing functional E51 antibody presents several technical challenges:

• Post-translational modification issues:

  • Ensuring proper tyrosine sulfation is critical but challenging in standard expression systems

  • Mammalian expression systems (especially CHO and HEK293) provide better sulfation capacity

  • Co-expression of tyrosylprotein sulfotransferases (TPST1/2) may enhance sulfation

• Expression system selection:

  • Bacterial systems generally fail to provide sulfation

  • Insect cell systems provide limited sulfation

  • Human cell lines offer optimal sulfation but may have lower yields

• Purification challenges:

  • Sulfated antibodies may exhibit altered binding to protein A/G

  • Charge heterogeneity due to variable sulfation requires optimized ion exchange chromatography

  • Desulfation can occur during purification under certain pH conditions

• Quality control:

  • Confirming proper sulfation using mass spectrometry

  • Ensuring batch-to-batch consistency in sulfation levels

  • Developing functional assays to confirm biological activity

How can researchers troubleshoot inconsistent neutralization results with E51?

When encountering inconsistent neutralization results with E51 antibody, researchers should systematically investigate the following factors:

• Antibody quality issues:

  • Verify sulfation status using mass spectrometry

  • Check for protein aggregation using size exclusion chromatography

  • Confirm binding activity to recombinant gp120 before neutralization assays

• Viral preparation variations:

  • Standardize viral stock preparation methods

  • Normalize viral input based on infectivity rather than p24 content

  • Consider using single-round infection assays with pseudoviruses

• Experimental design optimization:

  • Implement proper statistical approaches for dose-response modeling

  • Use four-parameter logistic models for calculating IC50 values

  • Ensure adequate sample sizes for statistical power

  • Include appropriate controls in each experiment

• Data analysis approaches:

  • Apply statistical methods to identify outliers

  • Use computational models to normalize between experiments

  • Consider Bayesian statistical approaches for more robust IC50 determinations

How might computational approaches improve understanding of E51's interaction with HIV-1 Env?

Advanced computational approaches offer promising avenues for deeper understanding of E51-Env interactions:

• Machine learning for epitope prediction:

  • Using neutralization panel data to identify key Env residues affecting E51 binding

  • Applying deep learning models to predict E51 neutralization of novel HIV-1 variants

  • Training neural networks on existing binding and neutralization data to predict cross-reactivity

• Molecular dynamics simulations:

  • Modeling the conformational changes in Env induced by E51 binding

  • Simulating the synergistic effects between E51 and CD4bs antibodies

  • Investigating the energetics of sulfotyrosine-gp120 interactions

• Antibody library design:

  • Using multi-objective linear programming with diversity constraints

  • Leveraging deep learning models to predict effects of mutations on antibody properties

  • Creating optimized E51 variants with enhanced breadth and potency

• Systems biology approaches:

  • Modeling the impact of E51-like antibodies in the context of polyclonal responses

  • Predicting viral escape pathways under E51 selection pressure

  • Simulating the evolution of antibody responses in infected individuals

What are the most promising research avenues for developing E51-based therapeutics?

Several research directions hold significant promise for developing E51-based therapeutics:

• Bispecific antibody development:

  • Creating antibodies that combine E51 with CD4bs binders like VRC01

  • Developing molecules that simultaneously target the CD4i epitope and other conserved regions

  • Engineering bispecifics that target both viral Env and cellular receptors (CD4/CCR5)

• E51-derived CCR5 mimetics:

  • Further development of CCR5mim2-Ig, which was developed from E51's CDR-H3 region

  • Optimization of sulfotyrosine positioning for maximum binding and neutralization

  • Combination with other inhibitory domains for enhanced potency

• Combinatorial antibody therapy:

  • Identifying optimal combinations of E51 with other broadly neutralizing antibodies

  • Developing formulations that maximize synergistic effects

  • Strategies to minimize viral escape through targeting multiple epitopes

• Novel delivery approaches:

  • Gene therapy for sustained E51 or E51-derivative expression

  • Nanoparticle delivery systems for improved tissue penetration

  • Vectored immunoprophylaxis approaches using E51-encoding genes

What are the recommended protocols for assessing E51 binding to conformational epitopes on HIV-1 Env?

For optimal assessment of E51 binding to conformational epitopes on HIV-1 Env, the following methodological approaches are recommended:

• Cell-surface Env binding assays:

  • Use 293T cells transiently transfected with Env-expressing plasmids

  • Include both wild-type and mutant Envs for comparison

  • Pre-incubate with soluble CD4 to induce the CD4i epitope

  • Detect E51 binding using flow cytometry with fluorescently-labeled secondary antibodies

  • Compare binding patterns with and without CD4 to confirm CD4-induced nature of the epitope

• BLI/SPR binding kinetics analysis:

  • Immobilize either E51 or Env protein on biosensor

  • For CD4i epitope studies, perform sequential binding: first CD4, then Env, then E51

  • Determine association (kon) and dissociation (koff) rates

  • Calculate binding affinity (KD) under different conditions

• Conformational ELISA:

  • Capture Env trimers using antibodies against non-competing epitopes

  • Pre-incubate with CD4 to expose CD4i epitopes

  • Apply E51 and detect binding

  • Include conformational controls to verify trimer integrity

• Hydrogen/deuterium exchange mass spectrometry:

  • Compare deuterium uptake patterns in Env with and without E51 binding

  • Identify regions with altered solvent accessibility upon binding

  • Map conformational changes induced by E51 interaction

What controls should be included when evaluating E51 and CD4bs antibody synergy?

When investigating synergistic effects between E51 and CD4bs antibodies, the following controls are essential:

• Antibody controls:

  • Individual antibodies at multiple concentrations to establish baseline activity

  • Isotype control antibodies to assess non-specific effects

  • Non-synergistic antibody combinations (e.g., E51+b12 or VRC01+2G12) as negative controls

  • CD4-Ig as a positive control for CD4i epitope exposure

• Viral variant controls:

  • Include HIV-1 isolates with known resistance to either E51 or CD4bs antibodies

  • Test against multiple clades to ensure breadth of synergistic effect

  • Include neutralization-resistant variants to test the limits of synergy

• Mechanistic controls:

  • Test E51 Fab fragments vs. whole IgG to assess the role of avidity

  • Compare wild-type E51 with tyrosine-sulfation mutants to determine the importance of sulfation

  • Test CD4bs antibodies with different footprints on gp120 (e.g., VRC01 vs. b12 vs. 3BNC117)

• Technical controls:

  • Include cell viability assessments to rule out toxicity effects

  • Test antibody combinations prepared separately vs. co-incubated to assess interaction effects

  • Include time-of-addition variations to determine temporal aspects of synergy

What statistical approaches are most appropriate for analyzing E51 neutralization data?

For robust analysis of E51 neutralization data, the following statistical approaches are recommended:

• Dose-response modeling:

  • Use four-parameter logistic regression to fit neutralization curves

  • Model the relationship between dose and neutralization using the equation:
    $y = L+(U - L)/(1 + (x/ID50)^h)$

  • Where L is the minimum value, U is the maximum value, ID50 is the inflection point, and h is the Hill slope

• Synergy analysis:

  • Apply Chou-Talalay combination index method for quantitative assessment of synergy

  • Calculate combination index (CI) values where CI<1 indicates synergy

  • Generate isobolograms to visualize synergistic, additive, or antagonistic effects

  • Compare observed vs. expected effects using Bliss independence model

• Statistical validation:

  • Perform power analysis to determine appropriate sample sizes

  • Use ANOVA with post-hoc tests for comparing multiple conditions

  • Apply bootstrapping or Bayesian methods for more robust IC50 confidence intervals

  • Implement mixed-effects models to account for batch variation

• Visualization techniques:

  • Use logarithmic scales for antibody concentration plots

  • Generate heat maps for comparing activity across multiple viral isolates

  • Create neutralization fingerprints to compare E51 with other antibodies

How should researchers interpret contradictory results between binding and neutralization assays with E51?

When faced with discrepancies between E51 binding and neutralization data, researchers should consider:

• Epitope accessibility factors:

  • Binding assays using monomeric gp120 may not reflect trimer accessibility

  • CD4i epitopes are often occluded on native trimers but exposed on monomers

  • E51 may bind isolates in vitro but fail to neutralize due to steric constraints

• Methodological considerations:

  • Binding assays measure affinity while neutralization assays measure functional inhibition

  • Different assay conditions (temperature, pH, buffers) may affect results

  • Time-dependent effects may influence neutralization but not binding results

• Resolution approaches:

  • Perform binding studies on trimeric Env rather than monomeric gp120

  • Use cell-surface expressed Env for binding studies to better mimic neutralization conditions

  • Compare E51 binding before and after CD4 engagement

  • Conduct time-of-addition experiments to assess kinetic factors

• Interpretation framework:

  • Strong binding with poor neutralization suggests accessibility issues

  • Poor binding with unexpected neutralization may indicate conformational effects

  • Isolate-specific effects may reveal important epitope variations

  • Consider the impact of CD4 levels on target cells used in neutralization assays